Redeye updates its estimates following Surgical Science’s Q3 2022 report, which we judge featured solid sales growth and profitability. We believe that weak cash flow during the quarter could be a concern if it persists long-term.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/